Search results with tag "Antirheumatic"
The EULAR points to consider for use of antirheumatic ...
e-lactancia.orgThe EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation Carina Götestam Skorpen,1,2,3 Maria Hoeltzenbein,4 Angela Tincani,5 Rebecca Fischer-Betz,6 Elisabeth Elefant,7 Christina Chambers,8 Josè da Silva,9 Catherine Nelson-Piercy,10 Irene Cetin,11 Nathalie Costedoat-Chalumeau,12,13 Radboud Dolhain,14 Frauke Förger,15 Munther Khamashta,16
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE …
www.rxabbvie.comantirheumatic drugs (DMARDs). 2.3 Procedures Prior to Treatment Initiation Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI [see Warnings and Precautions (5.3)]. Complete all age-appropriate vaccinations as recommended by current immunization guidelines [see Warnings and Precautions (5.4)].
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euanti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate (see sections 4.4, 4.5 and 5.1 for available data on different combinations). ... biologic and conventional disease- modifying antirheumatic drugs (DMARDs). If a patient develops herpes zoster, treatment should be temporarily interrupted until the ...
HIGHLIGHTS OF PRESCRIBING INFORMATION RINVOQ ... - …
www.rxabbvie.comdisease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended. 1.2 Psoriatic Arthritis RINVOQ is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
Drug Allergy: An Updated Practice Parameter - AAAAI
www.aaaai.orgdisease-modifying antirheumatic drugs, antimycobacterial drugs, biologic modifiers, immunosuppressive agents, immu-nomodulatory agents, complementary medications, and drug-induced granuloma with or without vasculitis. Significant updates to sections on cutaneous manifestations of drug re-actions, laboratory testing, -lactam allergy, cross ...
HIGHLIGHTS OF PRESCRIBING INFORMATION Psoriatic …
www.accessdata.fda.govnonbiologic disease-modifying antirheumatic drugs (DMARDs). 3 . Reference ID: 4269956 Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. Psoriatic Arthritis